Discover
NXTC
NextCure, Inc.
1.95
2 x 1.49
2 x 2.57
bid
ask
+
0.35
21.87%
2 @ 04:00 PM
1.85 -0.10 (5.13%)
| Ytd | -86.26% | |
| 1y | -62.72% |
1.61
day range
2.10
1.55
52 week range
15.74
| Open | 1.61 | Prev Close | 1.60 | Low | 1.61 | High | 2.10 | Mkt Cap | 7.04M |
| Vol | 77.97K | Avg Vol | 99.02K | EPS | -16.82 | P/E | N/A | Forward P/E | -0.66 |
| Beta | 0.79 | Short Ratio | 1.89 | Inst. Own | 57.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 6.24 | 200-d Avg | 9.68 | 1yr Est | 3.33 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.35 | -0.41 | -0.06 | -17.14% |
| 2024-08-01 | 2024-06 | -0.36 | -0.55 | -0.19 | -52.78% |
| 2024-08-01 | 2024-06 | -0.36 | N/A | N/A | N/A |
| 2024-05-02 | 2024-03 | -0.45 | -0.61 | -0.16 | -35.56% |
| 2024-05-02 | 2024-03 | -0.45 | N/A | N/A | N/A |
| 2024-03-21 | 2023-12 | -0.54 | -0.52 | 0.02 | 3.70% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-02 | Needham | Upgrade | Buy | Buy |
| 2024-06-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-31 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-03 | Needham | Upgrade | Buy | Buy |
Profile
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Sofinnova Investments, Inc. | 2.67M | 2.51M | 9.54% |
| 2024-09-29 | Logos Global Management LP | 2.50M | 2.35M | 8.93% |
| 2024-09-29 | Affinity Asset Advisors, Llc | 2.30M | 2.17M | 8.22% |
| 2024-09-29 | Orbimed Advisors LLC. | 1.14M | 1.07M | 4.07% |
| 2024-09-29 | Vanguard Group Inc | 987.32K | 929.07K | 3.53% |
| 2024-09-29 | Blackrock Inc. | 729.84K | 686.78K | 2.61% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 613.83K | 577.61K | 2.19% |
| 2024-07-30 | Federated Hermes MDT Mid Cap Growth Fund | 315.18K | 296.58K | 1.13% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 201.98K | 190.06K | 0.72% |
| 2024-07-30 | Vanguard Explorer Fund, Inc. | 171.52K | 161.40K | 0.61% |
| 2024-08-30 | BlackRock Advantage Small Cap Core Fund | 169.79K | 159.77K | 0.61% |
| 2024-09-29 | Delaware Group Equity Fds IV-Delaware Healthcare Fund | 150.00K | 141.15K | 0.54% |
Split
| Split | Date |
|---|---|
| 1 : 12 | 2025-07-14 |